Active

Resisting resistance: How melanoma cells survive targeted therapy

Cancer types:

Melanoma

Project period:

Research institute:

Vlaams Instituut voor Biotechnologie vzw

Award amount:

£170,180

Location:

Belgium

Researcher Professor Jean-Christophe Marine

Professor Jean-Christophe Marine and his team are trying to understand why some melanoma cells are able to go ‘dormant’ and survive targeted treatments, or even become resistant to the drug used. They hope to learn how to target these resistant cells and make treatments more effective for patients.

Hope for the future

One of the biggest issues when treating any cancer is that cells can become resistant to treatments, meaning a small number of cells can survive and multiply again once treatment is finished. If this happens, a patient’s cancer can return and they will have to try a different treatment, if an alternative is available.


Professor Marine and his team discovered that before melanoma cells become fully resistant to treatment, they go into a ‘dormant’ state that makes it harder for treatments to have an effect. They hope that studying how melanoma cells enter this dormant state will reveal a way to target these cells before resistance eventually develops, making treatments more effective for many cases of melanoma, and potentially for other types of cancer.

Meet the scientist

Professor Jean-Christophe Marine first realised that he wanted to study cancer for a living when working as a postdoc at St Jude’s Children’s Research Hospital in Memphis, USA. There, he worked on exciting projects with colleagues that shared his ambition to make a difference and help patients. Outside of the lab, he enjoys cooking for friends with a nice glass of wine and is a big sports fan.

The science

Minimal residual disease (MRD) in melanoma occurs when a small number of cells remain in the body after most other cancer cells have been wiped out by a treatment. Sometimes, the cells have become resistant to the treatment used and the cancer can come back. Professor Jean-Christophe Marine and his team have discovered that these cells can start to look like ‘starved’ melanoma cells (SMCs), where the cells go into a dormant-like state that makes them more resistant to treatment. Importantly, this seems to happen before the melanoma cells become fully drug resistant.


Professor Marine and his team now aim to understand the process that changes melanoma cells into SMCs and investigate how they might be able to target cells that are in this state. They hope that catching cells at this stage will prevent them becoming resistant to treatment and believe that targeting SMCs while a patient is receiving treatment may help to make sure all the melanoma cells are destroyed. This could greatly improve treatment outcomes for melanoma patients and possibly for people with other types of cancer.

Going to the lab every morning is exciting on so many levels, but above all it is the opportunity to contribute to a better understanding of cancer, which affects so many people worldwide - this is what drives me most.

Professor Jean-Christophe Marine

Related projects

Professor Sophia Karagiannis Team

Active United Kingdom

Melanoma

How can we help treatments work for more melanoma patients?

Immunotherapy currently does not work for half of all melanoma patients. This project hopes that understanding allergic reactions could lead to new solutions.

Researcher: Professor Sophia Karagiannis

Atchoo! Can understanding allergic reactions lead to new cancer treatments?

Active United Kingdom

Melanoma

Why do some melanoma patients stop responding to therapy?

Researchers hope to find new drug targets that could make immunotherapies more effective, making them a better option for more people with advanced melanoma.

Researcher: Dr Adam Hurlstone

Reversing resistance to immune checkpoint inhibitors

Active United Kingdom

Melanoma

How does melanoma adapt to spread and seed new tumours?

Cancers is easier to treat when caught early so this project hopes to reveal new treatments that could stop melanoma spreading, helping survival rates.

Researcher: Professor Victoria Sanz-Moreno

Understanding how melanoma adapts to spread and seed new tumours
Share this page